Seeking Alpha

Sequenom (SQNM) says it's achieved positive results from a study of its RetnaGene AMD...

Sequenom (SQNM) says it's achieved positive results from a study of its RetnaGene AMD laboratory-developed test, which is designed to accurately predict the risk of disease progression of age-related macular degeneration. The announcement was made during its presentation today at the 2012 Joint Meeting of the American Academy of Ophthalmology and the Asia-Pacific Academy of Ophthalmology in Chicago. Shares +0.3% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector